Mural Oncology plc (NASDAQ:MURA) Short Interest Update

Mural Oncology plc (NASDAQ:MURA) was the target of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 396,800 shares, a decline of 25.2% from the January 15th total of 530,200 shares. Currently, 2.6% of the company’s shares are short sold. Based on an average trading volume of 206,900 shares, the short-interest ratio is presently 1.9 days.

Mural Oncology Stock Performance

Shares of MURA stock traded up $0.03 during trading hours on Friday, hitting $4.29. The company had a trading volume of 67,600 shares, compared to its average volume of 182,120. The company’s fifty day moving average is $3.70 and its 200 day moving average is $3.52. Mural Oncology has a fifty-two week low of $2.87 and a fifty-two week high of $5.62.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Mural Oncology in a report on Monday, November 11th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in MURA. Point72 Asset Management L.P. acquired a new stake in Mural Oncology during the 3rd quarter worth approximately $340,000. Raymond James Financial Inc. acquired a new position in shares of Mural Oncology in the 4th quarter valued at $181,000. Virtu Financial LLC purchased a new position in Mural Oncology in the fourth quarter valued at approximately $129,000. Renaissance Technologies LLC raised its holdings in shares of Mural Oncology by 17.4% during the 4th quarter. Renaissance Technologies LLC now owns 238,465 shares of the company’s stock valued at $768,000 after buying an additional 35,403 shares during the period. Finally, Jane Street Group LLC acquired a new stake in Mural Oncology during the 4th quarter valued at approximately $68,000. Hedge funds and other institutional investors own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.